Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSichuan University
About this trial
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung cancer.
Eligibility criteria
Qualifiers
Men or women aged more than or equal to (≥) 18 years old and less than or equal to (≤) 75 years old
Histologically or cytologically confirmed ES-SCLC
No prior treatment for ES-SCLC
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Disqualifiers
Histopathologic or cytopathologic diagnosis of mixed small cell lung cancer or non-small cell lung cancer
Limited stage small cell lung cancer
Combination of poorly controlled malignant pleural or pericardial effusions requiring continuous drainage
Presence of active or symptomatic brain metastases or Leptomeningeal metastases
Trial design
Treatments tested in this trial
- Low-dose radiotherapy
- Etoposide
- Cisplatin
- Sugemalimab
- Olaparib
Treatment groups
45 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov